Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

• Status: Recruiting
• Trial end date: 2027-03-31
• Target enrollment: 0
• Participant gender: All

Summary

For high-risk stage II and stage III colorectal cancer, even after radical resection and postoperative adjuvant chemo/radiotherapy, 30-40% of patients will still have recurrence and metastasis. Thymosin-alpha 1 is believed to improve immunity and may help promote tumor immunity to reduce the incidence of recurrence and metastasis. This study hopes to verify the effecacy and safety of thymosin-alpha 1 for adjuvant treatment of high-risk stage II and stage III colorectal cancer after radical resection.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fudan University
• Treatments: Thymalfasin

Criteria

Inclusion Criteria:

• Colorectal cancer receiving radical resection

• Pathologically diagnosed with high-risk stage II or stage III

• Eastern Cooperative Oncology Group performance status of 0-2

• Adequate hepatic, renal, and hematologic function

Exclusion Criteria:

• Had previously taken any immune-promoting drugs

• Pregnancy or lactation